OKYO Pharma Total Debt vs. Current Valuation
| OKYO Stock | USD 1.06 0.01 0.93% |
For OKYO Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of OKYO Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well OKYO Pharma Ltd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between OKYO Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of OKYO Pharma Ltd over time as well as its relative position and ranking within its peers.
OKYO |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
OKYO Pharma Current Valuation vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining OKYO Pharma's current stock value. Our valuation model uses many indicators to compare OKYO Pharma value to that of its competitors to determine the firm's financial worth. OKYO Pharma Ltd is rated below average in total debt category among its peers. It is rated below average in current valuation category among its peers reporting about 4.59 of Current Valuation per Total Debt. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the OKYO Pharma's earnings, one of the primary drivers of an investment's value.OKYO Total Debt vs. Competition
OKYO Pharma Ltd is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 156 Million. OKYO Pharma holds roughly 7.42 Million in total debt claiming about 5% of equities under Health Care industry.
OKYO Current Valuation vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
OKYO Pharma |
| = | 7.42 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
OKYO Pharma |
| = | 34.04 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
OKYO Current Valuation vs Competition
OKYO Pharma Ltd is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 508.06 Million. OKYO Pharma holds roughly 34.04 Million in current valuation claiming about 7% of equities under Health Care industry.
OKYO Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in OKYO Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, OKYO Pharma will eventually generate negative long term returns. The profitability progress is the general direction of OKYO Pharma's change in net profit over the period of time. It can combine multiple indicators of OKYO Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -11.3 M | -10.7 M | |
| Operating Income | -15.7 K | -16.5 K | |
| Income Before Tax | -16.8 K | -17.6 K | |
| Total Other Income Expense Net | -1.1 K | -1.1 K | |
| Net Loss | -16.8 M | -16 M | |
| Income Tax Expense | 22.42 | 21.30 | |
| Net Loss | -4.6 M | -4.8 M | |
| Net Loss | -16.8 M | -16 M | |
| Net Interest Income | -1.1 M | -1 M | |
| Change To Netincome | 669.7 K | 636.2 K | |
| Income Quality | 0.56 | 0.47 | |
| Net Income Per E B T | 1.00 | 1.65 |
OKYO Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on OKYO Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of OKYO Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the OKYO Pharma's important profitability drivers and their relationship over time.
Use OKYO Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.OKYO Pharma Pair Trading
OKYO Pharma Ltd Pair Trading Analysis
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your OKYO Pharma position
In addition to having OKYO Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Funds Thematic Idea Now
Precious Metals Funds
Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
To fully project OKYO Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of OKYO Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include OKYO Pharma's income statement, its balance sheet, and the statement of cash flows.